NCT03357757 2025-06-26
LATENT
AHS Cancer Control Alberta
Phase 2 Completed
Clinical Trials
7 trialsNCT03440567 2025-03-26
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT03636503 2025-02-06
Rituximab + Immunotherapy in Follicular Lymphoma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03046953 2024-07-16
AVAIL-T
University of Birmingham
Phase 2 Completed
NCT03617666 2023-12-12
AVENuE
University College, London
Phase 2 Unknown
NCT03439501 2021-09-24
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]
Samsung Medical Center
Phase 2 Unknown
NCT03147404 2019-12-30
MS100070-0177
Samsung Medical Center
Phase 2 Completed